ZA202101688B - Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain - Google Patents

Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain

Info

Publication number
ZA202101688B
ZA202101688B ZA2021/01688A ZA202101688A ZA202101688B ZA 202101688 B ZA202101688 B ZA 202101688B ZA 2021/01688 A ZA2021/01688 A ZA 2021/01688A ZA 202101688 A ZA202101688 A ZA 202101688A ZA 202101688 B ZA202101688 B ZA 202101688B
Authority
ZA
South Africa
Prior art keywords
treatment
joint pain
pharmaceutical compositions
compositions suitable
articular delivery
Prior art date
Application number
ZA2021/01688A
Other languages
English (en)
Inventor
Tseng Yun-Long
Shih Sheue-Fang
Chang Po-Chun
Chang Lo
Original Assignee
Tlc Biopharmaceuticals Inc
Taiwan Liposome Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tlc Biopharmaceuticals Inc, Taiwan Liposome Co Ltd filed Critical Tlc Biopharmaceuticals Inc
Publication of ZA202101688B publication Critical patent/ZA202101688B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2021/01688A 2018-09-16 2021-03-12 Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain ZA202101688B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731941P 2018-09-16 2018-09-16
PCT/US2019/051247 WO2020056399A1 (en) 2018-09-16 2019-09-16 Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain

Publications (1)

Publication Number Publication Date
ZA202101688B true ZA202101688B (en) 2024-06-26

Family

ID=68084954

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/01688A ZA202101688B (en) 2018-09-16 2021-03-12 Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain

Country Status (15)

Country Link
US (1) US12208104B2 (enExample)
EP (1) EP3849522A1 (enExample)
JP (1) JP7634476B2 (enExample)
KR (1) KR20210060559A (enExample)
CN (1) CN112702993A (enExample)
AU (1) AU2019339528B2 (enExample)
BR (1) BR112021004880A2 (enExample)
CA (1) CA3112234A1 (enExample)
CL (1) CL2021000627A1 (enExample)
IL (1) IL281513B1 (enExample)
MX (1) MX2021003030A (enExample)
SG (1) SG11202102400PA (enExample)
TW (1) TWI843751B (enExample)
WO (1) WO2020056399A1 (enExample)
ZA (1) ZA202101688B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023537474A (ja) 2020-08-05 2023-09-01 ティーエルシー バイオファーマシューティカルズ、インク. 疼痛制御のための関節内コルチコステロイドの医薬組成物
EP4706666A1 (en) * 2023-05-05 2026-03-11 Xiangya Hospital, Central South University Use of magnesium hydroxide in preparation of drug for treating arthralgia
IL327816A (en) * 2023-11-03 2026-06-01 Taiwan Liposome Co Ltd Liposomal composition of intra-articular corticosteroid for pain control

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152962A1 (en) * 2002-06-12 2005-07-14 Metselaar Josbert M. Composition for treatment of inflammatory disorders
EP1371362A1 (en) * 2002-06-12 2003-12-17 Universiteit Utrecht Holding B.V. Composition for treatment of inflammatory disorders
AU2013216861B2 (en) 2012-02-10 2017-05-18 Tlc Biopharmaceuticals, Inc Pharmaceutical compositions to reduce complications of ocular steroid
BR112015000174A2 (pt) * 2012-07-05 2017-06-27 Taiwan Liposome Co Ltd método para o tratamento da artrite

Also Published As

Publication number Publication date
IL281513B1 (en) 2026-07-01
IL281513A (en) 2021-04-29
AU2019339528A1 (en) 2021-04-15
AU2019339528B2 (en) 2025-01-30
TW202023569A (zh) 2020-07-01
WO2020056399A1 (en) 2020-03-19
EP3849522A1 (en) 2021-07-21
TWI843751B (zh) 2024-06-01
KR20210060559A (ko) 2021-05-26
US12208104B2 (en) 2025-01-28
CA3112234A1 (en) 2020-03-19
US20210338688A1 (en) 2021-11-04
CN112702993A (zh) 2021-04-23
JP2022500364A (ja) 2022-01-04
SG11202102400PA (en) 2021-04-29
MX2021003030A (es) 2021-05-27
BR112021004880A2 (pt) 2021-06-01
JP7634476B2 (ja) 2025-02-21
CL2021000627A1 (es) 2021-09-10

Similar Documents

Publication Publication Date Title
PH12021551792A1 (en) Bi-ligand drug conjugate and use thereof
MX2024001201A (es) Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con agonistas de glp-1 para usarse en tratar enfermedades del higado graso.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2014000130A (es) Procedimientos y composiciones para la inhibicion de resorcion osea.
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
EA200870469A1 (ru) Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение
UA98462C2 (ru) Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
PH12019502651A1 (en) Use of vibegron to treat overactive bladder
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
MX2007000967A (es) Composiciones de risedronato y metodos para su uso.
IL272036B1 (en) Methods and compositions for treatment of pain using capsaicin
CL2021000627A1 (es) Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular
HRP20240812T1 (hr) Oblici doziranja i terapijska primjena l-4-klorokinurenina
EP4389218A3 (en) Composition for treating joint disease and kit containing same
ZA202100604B (en) Methods to reduce complications of intra-articular steroid
PH12022551043A1 (en) Combination of a cxcr7 antagonist with an s1p1 receptor modulator
MX2021015796A (es) Composiciones y metodos para tratar enfermedades oculares.
BR112014001503A2 (pt) composições farmacêuticas compreendendo 4-bromo-n-(imidazolidin-2-ilideno)-1h-benzimidazol-5-amina para o tratamento de doenças de pele
ZA202200331B (en) Naltrexone formulation
PH12020551493A1 (en) Triazacyclododecansulfonamide (``tcd``)-based protein secretion inhibitors
WO2018136647A3 (en) Therapeutic use of beta-lactams in hematopoiesis, immuno-oncology therapy, and regulation of lipoprotein and apolipoprotein levels
EA202092944A1 (ru) Применение пероральных распадающихся таблеток рилузола для лечения заболеваний